---
id: 037
title: Aminoglycoside Spectrum and Toxicity Comparison
category: antimicrobials
subcategory: aminoglycosides
tags: [aminoglycoside, gentamicin, tobramycin, amikacin, nephrotoxicity, ototoxicity, GAT]
difficulty: medium
---

## Question

Compare the three major aminoglycosides (**gentamicin, amikacin, tobramycin**) in terms of spectrum and toxicity. Use **GAT** mnemonic.

## Answer

### **GAT mnemonic for aminoglycosides:**

| Feature | **G**entamicin | **A**mikacin | **T**obramycin |
|---------|----------------|--------------|----------------|
| **Spectrum** | Broad Gram-neg | Broadest (resistant organisms) | Best *Pseudomonas* |
| **Resistance** | Common | Least resistant | Intermediate |
| **Nephrotoxicity** | Medium | Least toxic | Medium |
| **Ototoxicity type** | **Vestibular** > cochlear | **Cochlear** > vestibular | **Equal** (both) |
| **Typical use** | General Gram-neg infections | Resistant organisms, TB | *Pseudomonas*, CF |

### **Spectrum Coverage:**
- **All aminoglycosides:** Aerobic Gram-negatives (Enterobacterales, *Pseudomonas*, *Acinetobacter*)
- **All aminoglycosides:** Synergy vs Gram-positives (*Staph*, *Enterococcus*) when combined with cell wall agents
- **None cover:** Anaerobes, Streptococci (alone), atypicals

### **Amikacin Advantages:**
- Active against aminoglycoside-modifying enzyme (AME)-producing organisms
- Retained activity when gentamicin/tobramycin resistant
- Used for MDR Gram-negatives and *Mycobacterium* (TB, NTM)

### **Tobramycin Advantages:**
- **2-4× more active** than gentamicin vs *P. aeruginosa*
- Preferred for cystic fibrosis pulmonary exacerbations
- Inhaled formulation available (TOBI)

## Key Points

### **Toxicity Rates:**
- **Nephrotoxicity:** 10-25% (usually reversible)
- **Ototoxicity:** 2-45% (often **irreversible**)
- **Risk factors:** Duration >5 days, high trough levels, elderly, concurrent nephrotoxins (vancomycin, loop diuretics)

### **Ototoxicity Specifics:**
- **Vestibular damage** (gentamicin, tobramycin) → vertigo, ataxia, nystagmus
- **Cochlear damage** (amikacin, kanamycin) → hearing loss (high frequencies first)
- **Mitochondrial mutations** (m.1555A>G) → increased risk even at therapeutic levels

### **Clinical Pearls:**
- **Avoid in:**Acidic/hypoxic environments (abscess, empyema) - poor penetration
- **Dose by actual body weight** (not adjusted/ideal)
- **Monitor:** SCr, trough levels, hearing/vestibular function if >5 days

## Sources

- [StatPearls: Aminoglycosides NBK541105]
- [PMC: Aminoglycoside-Related Nephrotoxicity and Ototoxicity 2023]
- [UK Drug Safety 2024: Mitochondrial Mutations and Deafness Risk]

## Media

N/A
